FDA OKs Ixempra for advanced breast cancer

Oct 22, 2007

The U.S. Food and Drug Administration has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or advanced breast cancer.

"This approval is important because it provides certain patients with a new chemotherapy option in instances where other drugs have failed," said Dr. Douglas Throckmorton, deputy director of the FDA's Center for Drug Evaluation and Research.

Ixempra (ixabepilone) was approved for use in combination with another cancer drug, capecitabine, in patients who no longer respond to two other chemotherapy treatments. The prior treatments included an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel).

Ixempra, which is administered by intravenous infusion, was also approved for use alone in patients who no longer benefit from an anthracycline, a taxane and capecitabine.

The drug is distributed by the Bristol-Meyers Squibb Co. of Princeton, N.J.

Copyright 2007 by United Press International

Explore further: Police seize millions in huge fake Viagra swoop

add to favorites email to friend print save as pdf

Related Stories

Some anti-inflammatory drugs affect more than their targets

Aug 21, 2014

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved ...

Advancing medicine, layer by layer

Jul 02, 2014

Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor ...

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

12 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

gdpawel
4 / 5 (2) Oct 26, 2007
As we enter the era of "personalized" medicine, it is time to take a fresh look at how we evaluate treatments for cancer patients. More emphasis should be put on matching treatment to the patient. Patients would certainly have a better chance of success had their cancer been chemo-sensitive rather than chemo-resistant, where it is more apparent that chemotherapy improves the survival of patient, and where identifying the most effective chemotherapy would be more likely to improve survival.

Ixempra would be the first in a new class of chemotherapy drugs called epothilones. The medicine, which is injected, works by inhibiting tubulin, a protein that acts like a scaffold inside cancer cells and is necessary for their proliferation. Known generically as ixabepilone, the drug tries to stymie tumors by keeping cancer cells from replicating successfully. Ixempra would be used alone or in combination with Xeloda, in patients who have failed two or three other chemo drugs.

The FDA's approval of a Bristol-Myers Squibb drug harkens back to the old-school for breast cancer patients who aren't responding to other treatments. For use by women who have tried - without success - prior types of treatment? Why not give them the "right" drug or combinations the "first" time around? Why not have a bio-marker to aid the physician in selecting an effective agent or combination of agents the first time around, to avoid exposing the patient to ineffective harmful drugs, reducing the cost and decreased quality of life associated with ineffective treatment? Everyone would agree that the earlier in the course of the disease that the most active treatment is given, the better the result for the patient.

The downside of Ixempra is that chemo that goes after dividing cells, also attacks healthy cells along with cancerous ones. Ixempra%u2019s side effects include fatigue, hair loss and anorexia. Patients may experience a decrease in red blood cells, muscle pain, joint pain, the feeling of pins and needles in their fingers and toes, and in severe cases, inability to use their hands and feet fully. Does Taxol sound familiar?

Scores of "new" cancer drug applications are for me-too drugs which might show only miniscule clinical improvement in trials, yet they somehow gain approval. So, for 1.6 months longer, patients can suffer from one or all of the above and still end up dead. Since they are marketed as if they were important new breakthroughs, they have very high prices. For most patients the total cost of a full course of Ixempra is expected to run from $18,440 to $23,050. Does Abraxane sound familiar?

There have been truly minuscule improvements as a result of adjuvant chemotherapy and the net benefit to the community of breast cancer patients in the real world isn't all that clear. And the criticism remains: All of the clinical trials resources have gone toward driving a square peg (one size fits all chemotherapy) into a round hole (notoriously heterogeneous disease).
Johnson_Chen
not rated yet Jan 16, 2008
HealthLat is inviting patients who take Ixempra to report their experiences with the new drug. Your experiences will help patients needed and make money for you.

You are also welcome to check how Ixempra has been used by other patients. It is free.

For details, please visit: http://www.healthlat.com